ReviewPharmacy (Basel, Switzerland)2020
Cystatin C: A Primer for Pharmacists.
Review in Pharmacy (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 53 citations in OpenAlex.
- Evaluation of Kidney Function in Cirrhosis: Methods and Pitfalls.Diagnostics (Basel, Switzerland) · 2026Review
- Direct Measurement of GFR: Who, When, and How?: A Practical Approach Emphasizing Iohexol Plasma Clearance.Journal of the American Society of Nephrology : JASN · 2026Review
- Use of a Cystatin C-Based GFR Equation in a Population Pharmacokinetic Model of Methotrexate Clearance in Adult Patients with Lymphoma.Clinical pharmacokinetics · 2026Article
- Impact of Estimated Glomerular Filtration Rate Equations on Vancomycin Dosing and Treatment Outcomes.Drug design, development and therapy · 2026Article
- Optimal Piperacillin/Tazobactam Dosing in Adults with Low Body Weight: A Population Pharmacokinetic and Simulation-Based Study.Drug design, development and therapy · 2026Observational
- Renal safety of postoperative short-term use of flurbiprofen axetil in well-controlled hypertensive patients: a prospective multicenter cohort study.Frontiers in pharmacology · 2026Article
- Novel Kidney Biomarkers and Antibiotics-Induced Acute Kidney Injury: A Practical Assessment of Current and Future Applications.Clinical and translational science · 2025Review
- Utility of serum cystatin C measured at diagnosis in evaluating cross-sectional activity and predicting all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis.Clinical rheumatology · 2025Article
- Piperacillin/tazobactam clearance predicted by non-creatinine based estimates of GFR in critically ill adults.International journal of antimicrobial agents · 2025Article
- Comparison of GFR estimation equations using creatinine, cystatin C, and their combination in pediatric hematology-oncology: no single equation is superior across subgroups.Pediatric nephrology (Berlin, Germany) · 2025Article
- Impact of Removing Race Coefficient from Glomerular Filtration Rate Estimation Equations on Antidiabetics Among Black Patients.Pharmacy (Basel, Switzerland) · 2025Article
- Impact of postoperative flurbiprofen axetil on renal function in spontaneously hypertensive rats.Frontiers in pharmacology · 2025Article
- Challenges in renally eliminated medication use: Evaluating cystatin C and serum creatinine eGFR discordance.Pharmacotherapy · 2024Article
- Exploring Renal Function Assessment: Creatinine, Cystatin C, and Estimated Glomerular Filtration Rate Focused on the European Kidney Function Consortium Equation.Annals of laboratory medicine · 2024Review
- Impact of Various Estimated Glomerular Filtration Rate Equations on the Pharmacokinetics of Meropenem in Critically Ill Adults.Critical care explorations · 2023Article
- Cystatin C based estimation of chronic kidney disease and amyotrophic lateral sclerosis in the ALS registry Swabia: associated risk and prognostic value.Scientific reports · 2023Article
- Medication Management in the Critically Ill Patient with Acute Kidney Injury.Clinical journal of the American Society of Nephrology : CJASN · 2023Review
- Steering Away from Current Amoxicillin Dose Reductions in Hospitalized Patients with Impaired Kidney Function to Avoid Subtherapeutic Drug Exposure.Antibiotics (Basel, Switzerland) · 2022Article
- Article
- Kidney Function Assessment in African American Patients: A Narrative Review for Pharmacists.Pharmacy (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Pharmacists are at the forefront of dosing and monitoring medications eliminated by or toxic to the kidney. To evaluate the effectiveness and safety of these medications, accurate measurement of kidney function is paramount. The mainstay of kidney assessment for drug dosing and monitoring is serum creatinine (SCr)-based estimation equations. Yet, SCr has known limitations including its insensitivity to underlying changes in kidney function and the numerous non-kidney factors that are incompletely accounted for in equations to estimate glomerular filtration rate (eGFR). Serum cystatin C (cysC) is a biomarker that can serve as an adjunct or alternative to SCr to evaluate kidney function for drug dosing. Pharmacists must be educated about the strengths and limitations of cysC prior to applying it to medication management. Not all patient populations have been studied and some evaluations demonstrated large variations in the relationship between cysC and GFR. Use of eGFR equations incorporating cysC should be reserved for drug management in scenarios with demonstrated outcomes, including to improve pharmacodynamic target attainment for antibiotics or reduce drug toxicity. This article provides an overview of cysC, discusses evidence around its use in medication dosing and in special populations, and describes practical considerations for application and implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.